The energy harvesting efficiency is of tremendous importance for the realization of a high output-power nanogenerator serving as the basis for self-powered electronics. Here we report that the device performance of a sound-driven piezoelectric energy nanogenerator (SPENG) is remarkably improved by controlling both the carrier density and the interfacial energy in a semiconducting ZnO nanowire (NW), thereby achieving its intrinsic efficiency limits. A SPENG with carrier-controlled ZnO NWs exhibits excellent energy harvesting characteristics with an average power density of 0.9 mW cm⁻³, as well as a near 50 fold increase in both output voltage and current compared to those of a conventional ZnO NW. In addition, we demonstrate for the first time that an optimized SPENG is large enough and very suitable to drive electrophoretic ink displays based on voltage-drive systems. This fundamental progress makes it possible to fabricate high performance nanogenerators for viable industrial applications in portable/wearable personal electronics such as electronic papers and smart identity cards.

Lee S, et al. Yonsei Med J. 2022 Jan;63(Suppl):S93-S107. https://doi.org/10.3349/ymj.2022.63.S93

We have shown the enhanced piezoelectricity by electrostatic effects on a textile based platform. The electrostatic and piezoelectric effects were hybridized by integrating piezoelectric ZnO nanowires and a charged dielectric film on a wearable textile substrate. The hybrid textile nanogenerator produced an output voltage of 8 V and an output current of 2.5 μA. Using a simple AC–DC converter circuit, we operated the green organic light-emitting diode and a liquid crystal display panel using a 100 dB sonic wave.

Background and Purpose: Unlike clinical atrial fibrillation (AF), the significance of subclinical AF (SCAF) burden in patients with permanent pacemakers has not been fully evaluated. Methods: We investigated whether the SCAF burden was associated with increased risks of composite adverse outcomes, including progression to clinical AF, ischemic stroke, myocardial infarction, heart failure-related hospitalization, or cardiac death, in patients without previous AF. To quantify the 6-month SCAF burden, the total cumulative time spent in SCAF during every 6-month follow-up was summed. Results: During the median 5.2-year follow-up, 496 consecutive permanent pacemaker patients were classified into the no SCAF (no SCAF episode in any device analysis; n=152), low-burden SCAF (6-month SCAF <24 hours in at least one device analysis; n=287), or high-burden SCAF (6-month SCAF ≥24 hours in at least 1 device analysis; n=57) groups. The risk of composite adverse outcomes was greatest in the high-burden SCAF group ( P <0.001) and was primarily driven by progression to clinical AF ( P <0.001) and ischemic stroke ( P <0.001). The presence of high-burden SCAF, which always preceded ischemic stroke events, was independently associated with composite adverse outcomes (odds ratio=20.1 [95% CI, 7.60−52.7], P <0.001) and progression to clinical AF (odds ratio, 36.2 [95% CI, 15.9−87.8], P <0.001). Conclusions: In permanent pacemaker patients without preexisting AF, the presence of high-burden SCAF was closely associated with increased risks of composite adverse outcomes, particularly progression to clinical AF and ischemic stroke. Therefore, prospective studies deserve to be performed on the optimal anticoagulation therapy for permanent pacemaker patients with both high-burden SCAF and high stroke risk.